SAB Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for SAB Biotherapeutics (SABS).

Price Target Range — 11 Quarters

Analyst Consensus — 12 Analysts

12Buy

Consensus RatingBuy# Analysts12Avg. Consensus PT$11Upside to Avg. PT+282.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jun 24, 2026	Barclays	Eliana Merle	Initiate	Overweight	$13
Jun 17, 2026	Chardan Capital	Keay Nakae	PT Raise	Buy	$14→$16
Jun 15, 2026	Leerink Partners	Thomas Smith	PT Raise	Outperform	$7→$12
Jun 15, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$10
May 22, 2026	Citigroup	Samantha Semenkow	Initiate	Buy	$11
May 20, 2026	Jefferies	Roger Song	Initiate	Buy	$11
May 12, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$7→$10
May 11, 2026	Rodman & Renshaw	Seema Sheoran	Maintained	Buy	$13
Apr 2, 2026	Rodman & Renshaw	Seema Sheoran	Initiate	Buy	$13
Mar 11, 2026	Chardan Capital	Keay Nakae	PT Raise	Buy	$12→$14
Mar 10, 2026	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$9→$7
Jan 7, 2026	UBS	Michael Yee	Initiate	Buy	$7
Dec 19, 2025	Guggenheim	Yatin Suneja	Initiate	Buy	$15
Dec 18, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$12
Nov 17, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$12
Sep 19, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$12
Sep 17, 2025	Leerink Partners	—	Initiate	Outperform	$7
Aug 8, 2025	Chardan Capital	Keay Nakae	PT Cut	Buy	$20→$12
Jul 22, 2025	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$10→$9
May 15, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$20

Analyst Ratings News

PRO
Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13

Barclays analyst Eliana Merle initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Overweight rating and announces Price Target of $13.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16

Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and raises the price target from $14 to $16.

Benzinga Newsdesk

Paychex To Rally More Than 39%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on top names. See all rating changes on our analyst ratings page. Barclays, Wells Fargo, Piper Sandler, Leerink Partners, Truist Securities, and Citigroup updated their price targets and ratings for AVA, LEN, GMED, SABS, PDM, and PAYX. Evercore ISI Group and Truist Securities also raised their price targets and ratings for LEN and DDOG.

Avi Kapoor

PRO
Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12

Leerink Partners analyst Thomas Smith maintains SAB Biotherapeutics (NASDAQ:SABS) with a Outperform and raises the price target from $7 to $12.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $10 price target.

Benzinga Newsdesk

PRO
Citigroup Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11

Citigroup analyst Samantha Semenkow initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $11.

Benzinga Newsdesk

SAB Biotherapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

SAB Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13

PRO
Chardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16

Paychex To Rally More Than 39%? Here Are 10 Top Analyst Forecasts For Monday

PRO
Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12

PRO
HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $10 Price Target

PRO
Citigroup Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11

People Also Watch

People Also Watch

SAB Biotherapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

SAB Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13

PROChardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16

Paychex To Rally More Than 39%? Here Are 10 Top Analyst Forecasts For Monday

PROLeerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12

PROHC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $10 Price Target

PROCitigroup Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11

People Also Watch

People Also Watch

PRO
Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13

PRO
Chardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16

PRO
Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12

PRO
HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $10 Price Target

PRO
Citigroup Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11